Answers are grounded in this paper and cite their sources.
In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).
No takes yet. Share an insight, caveat, or question.
Kelly et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: